Home Blog Page 1925

Xinhua Silk Road: China’s Tianjin, Jilin and Guangdong unveil joint proposal to deepen exchanges and cooperation in agriculture

By
Advertorial Desk
-

BEIJING, Oct. 20, 2025 /PRNewswire/ — The 22nd China International Agricultural Trade Fair recently kicked off in northern China’s Tianjin Municipality. During the event, Tianjin Municipality, Jilin Province and Guangdong Province jointly released the proposal on deepening exchanges and cooperation in agriculture.

According to the proposal, the three regions will focus on key areas such as information sharing, standard setting, and market connectivity, with the aim of improving cooperation mechanisms and exploring new models for cross-regional development in agriculture.

In the future, the three regions will dynamically draw industry maps and break down data barriers in the monitoring of agricultural product market prices across regional markets, and harness data to empower corporate decision-making, better match supply and demand, and ensure the smooth and efficient flow of agricultural products.

Efforts will also be made to promote the inter-regional flow of key production factors such as technology, capital, and data.

By leveraging the factor resource trading platforms of the three regions and the policy advantages of pilot free trade zones and bonded areas, the three regions will work together to reduce the costs of factor mobility and innovation, and boost market vitality.

Original link: https://en.imsilkroad.com/p/347960.html

State Grid Gansu Linxia Power Supply Company: Solidly carry out special inspections after rain to strengthen the safety defense line of the power grid

By
Advertorial Desk
-

LINXIA, China, Oct. 20, 2025 /PRNewswire/ — On the evening of October 8th, the Linxia area experienced a significant rainfall. In order to promptly inspect the hidden dangers of power grid equipment after the rain and ensure the safe and reliable power supply, the State Grid Linxia Power Supply Company quickly responded and organized operation and maintenance personnel to conduct special inspections of power facilities in the jurisdiction, including important lines, substations, and low-lying areas, to fully ensure the safe and stable operation of the Linxia power grid.

State Grid Linxia Power Supply Company carefully deployed inspection forces and formed multiple special inspection teams to go to the front line. At the inspection site of the power transmission and distribution lines, the staff adopted a three-dimensional inspection mode of “drone aerial photography + foot inspection” to focus on inspecting the lines along the riverbank, low-lying areas, and geological hazard points. Carefully check whether the tower foundation is sunk, whether the cable is firm, and whether the insulator is broken or flashover marks. Clean up the tree debris and floating objects in the line passage at the same time to eliminate the risk of foreign objects hanging.

For core facilities such as substations, operation and maintenance personnel conducted “carpet-style” inspections, focusing on checking the leakage and water accumulation in cable trenches and cable shafts, testing the temperature and humidity inside switch cabinets to ensure the insulation performance of equipment, clearing debris from drainage pipes, verifying the reserve of flood prevention materials, and using infrared thermometers to accurately measure the temperature of key equipment such as transformers and circuit breakers to ensure good equipment operating conditions.

Next, the State Grid Linxia Power Supply Company will regularly carry out special inspections and hazard investigations after rain, continuously improve the health level of equipment and emergency response capabilities, effectively strengthen the safety defense line of the power grid, and provide strong power support for the economic and social development of the entire state and the lives of the people.

CoinLander Launches RWA Platform, Unlocking Stable Returns from Tokenized Real Estate Mortgages

By
Advertorial Desk
-

Platform Democratizes Access to Real-World Asset (RWA) Investments, Merging Tangible Security with Blockchain Efficiency

ROAD TOWN, British Virgin Islands, Oct. 20, 2025 /PRNewswire/ — CoinLander has officially launched, presenting a groundbreaking RWA (Real-World Asset) platform for investors seeking stable returns beyond speculative digital assets. The platform transforms illiquid real-world mortgages into accessible, tokenized investments, providing a target minimum of 6% Annual Percentage Rate (APR), all secured by tangible real estate.

This launch marks a pivotal step in the convergence of traditional finance (TradFi) and decentralized web3. Founded in 2024 by RΞN, a veteran of TradFi asset management with 20 years of experience, CoinLander is built to deliver a performance-driven alternative to volatile crypto yields. The platform leverages the security of physical property with the transparency and accessibility of blockchain, creating a robust RWA investment vehicle.

CoinLander Launches RWA Platform, Unlocking Stable Returns from Tokenized Real Estate Mortgages
CoinLander Launches RWA Platform, Unlocking Stable Returns from Tokenized Real Estate Mortgages

How It Works: Simplicity and Transparency

CoinLander demystifies real estate investing through a streamlined, four-step process:

  1. Select a Pool: Browse real estate-backed investment pools with clear terms on returns, risk, and duration.
  2. Invest with USDT: Easily fund your investment using USDT stablecoins.
  3. Earn Monthly Yield: Receive consistent, passive income directly to your wallet from borrower mortgage payments.
  4. Recover Principal: Get your initial investment back at the loan term’s end, ready to reinvest or withdraw.

Security First: The Tangible Backing of RWA

In a digital asset space often defined by speculation, CoinLander establishes trust through concrete, real-world security. Every investment is secured by a legal lien on physical property, ensuring that yields are generated by a sustainable business model—not market hype. This RWA-backed approach provides investors with unparalleled peace of mind, knowing their capital is protected by hard assets.

By significantly lowering the capital barriers to real estate debt, CoinLander is democratizing an RWA class once reserved for institutional giants. It offers a reliable, non-correlated anchor for any portfolio, designed to generate predictable returns regardless of crypto market conditions.

To find out more about the platform and how you can invest in tokenized real estate, head over to  Website | Twitter | Telegram | LinkedIn 

About CoinLander

CoinLander is a pioneering Real World Asset (RWA) platform that bridges the gap between traditional finance and the digital asset economy. It tokenizes high-quality, real-life mortgage investments, allowing users to earn predictable monthly interest backed by tangible property assets. The platform transforms illiquid real estate debt into accessible digital investments, offering a stable alternative to the volatility of traditional crypto markets.

Japan Funds New School in Bokeo, Strengthening Education, Development Ties

By
Laotian Times
-
The signing agreement (Photo: laophattananews)

Bokeo Province is set to welcome a new school with support from the Japanese government, contributing over USD 88,000 under the “Project for the Construction of Hatsa Lower Secondary School Building in Bokeo Province.”

Continue

AXA launches “WealthAhead II Savings Insurance” Series

By
Advertorial Desk
-

Empowering Customers to Accelerate Wealth and Plan for Succession Efficiently
Market-first[1] Wealth Master Service [2]Customised Trust-like[3] Cash Flow Solutions for Up to Three Recipients

HONG KONG, Oct. 20, 2025 /PRNewswire/ — AXA Hong Kong and Macau (“AXA”) has launched the new WealthAhead II Savings Insurance Series[4]  (“WealthAhead II Series“ or the “Series“), an enhanced successor to the widely popular WealthAhead Savings Plan. WealthAhead II Series strengthens wealth management, wealth allocation, as well as wealth succession, supporting customers to grow their wealth efficiently with enhanced liquidity. WealthAhead II Series introduces the market-first1 Wealth Master Service[2], enabling customers to pre-set periodic withdrawal instructions to build cash flows for up to three designated recipients. Additionally, the Series incorporates trust-like[3] features such as the Heritage Protector Option, which allows customers to pre-set succession events — including death or incapacitation — specify the designated age for inheritance, and appoint contingent owner and interim owner[5], ensuring secure and smooth wealth across generations.

Janet Lee, Chief Life and Health Insurance Officer of AXA Hong Kong and Macau, said: “With the US Federal Reserve initiating its first rate cut of the year and signalling the beginning of a broader easing cycle, markets are anticipating two further reductions within the year. Against this evolving macroeconomic backdrop, investors are increasingly prioritising long-term, stable asset allocation strategies that offer growth potential. Noting that today’s wealth management needs extend beyond simple savings or high returns. Customers are seeking holistic solutions that encompass asset accumulation, liquidity management, legacy planning and strategic wealth distribution across different life stages. In response, we have introduced WealthAhead II Series, which retains the strong total return potential of its predecessor while incorporating the market-first[1] Wealth Master Service[2] and trust-like[3] wealth succession tool. These enhancements empower customers to manage their wealth with greater flexibility, enabling them to plan effectively for wealth transition and succession, achieving their financial goals while meeting wealth distribution needs throughout every stage of life.”

Three Key Highlights of the WealthAhead II Series Include:

  1. Multi–currency options to capture global opportunities with flexible convertibility and gain lock-in features
    WealthAhead II Series offers premium payment terms of 5 and 10 years, with a choice of up to 9 currencies[6]. It also includes flexible currency conversion option[7]. From the third policy anniversary onwards, customers may convert their policy to another currency without affecting the total cash value or incurring any handling fees — enabling agile asset reallocation in response to market movements. The Series also features a Policy Value Lock-in Option[8], allowing customers to secure gains at opportune moments and mitigate future volatility. Additionally, the market-first dual-currency account[9] acts as a flexible cash reserve, with interest payable on the selected currency.
  2. Flexible Wealth Management – Personalised Wealth Allocation in Action
    WealthAhead II Series introduces the market-first[1] Wealth Master Service[2], enabling customers to pre-set periodic withdrawal instructions tailored for up to three designated recipients. Payments are made automatically at scheduled intervals, creating personalised income streams that support precise and strategic wealth distribution. The Series also features a Flexi Segregation Option. From the first policy anniversary onwards, customers can transfer part of the value from existing policy to a separate policy and subsequently exercise different policy options for each — ensuring the solution aligns with the distinct financial goals of individual family members.
  3. Steady Wealth Accumulation Across Generations – Ensuring Seamless Wealth Transfer
    The Series offers a suite of features designed to help customers safeguard their legacy and support intergenerational wealth planning. At the policy level, customers may arrange for policy continuation and succession by designating a contingent owner, interim owner, contingent insured, or by exercising the change of insured option. Additionally, customers may also appoint a designated executor and select from a range of death benefit settlement options to facilitate direct and efficient wealth distribution to family members.
    • Heritage Protector Option[10] – From policy commencement, customers can proactively plan for succession by appointing a contingent owner and, if necessary, an interim owner. They may specify the succession event — such as death or incapacitation — and set a designated age for succession. If the contingent owner has not reached the specified age at the time of the succession event, the interim owner will assume ownership and manage the policy in accordance with the granted right predefined by the client, ensuring that wealth is transferred securely and in line with the client’s intentions.
    • Flexi Continuation Option – From policy commencement, customers may designate a contingent insured[11] to allow part of the policy to continue following the passing of the current insured, while also providing a compassionate benefit. This feature enables a flexible balance between life protection and wealth transfer.
    • Change of Insured Option[12]– Starting from the first policy anniversary, customers may change the insured an unlimited number of times, allowing substantial wealth to be passed down through generations.
    • Flexi Care Option[13] – From policy commencement, customers may appoint a designated executor. In the event of the policy owner’s mental or physical incapacitation, the designated executor may apply for a one-time withdrawal of a certain percentage of the total cash value, without the need for complex legal procedures.
    • Tailored Death Benefit Settlement Options – Customers may select different settlement methods for each beneficiary, including lump sum payment, payment by instalments, or hybrid payments, to meet their legacy planning goals. Irrespective of the chosen option, customers may defer the first payment of death benefit for up to 30 years[14], allowing beneficiaries to receive the proceeds at the most appropriate time.

Enjoy a total reward of up to 80%[15] of the first-year premium during the promotional period. For more information, please visit: https://axa.com.hk/en/wealth-ahead-ii-savings-insurance

The above information is for reference only. For full details on the promotional offer, product features, terms, conditions, and exclusions, please refer to the relevant product brochure, policy contract, and promotional leaflet.

[1] The information refers to the service of periodic withdrawal with up to 3 recipients of withdrawal payments. The information refers to Hong Kong market only and is based on a comparison of periodic withdrawal arrangements offered by insurers for Long-Term Businesses as defined by the Insurance Authority in the Register of Authorised Insurers in Hong Kong as of July 2025.

[2] Wealth Master Service is an administrative service arrangement offered by the Company and not a plan feature of “WealthAhead II Savings Insurance” Series. Any application for the service is subject to the Company’s approval at its sole and absolute discretion, any applicable laws, regulations and guidelines and the administrative rules of the Company from time to time.

[3]  “Trust-like” indicates that the design concept of “WealthAhead II Savings Insurance” Series draws from the flexibility and precision of trust, but does not imply it is equivalent to a trust product.

[4] “WealthAhead II Savings Insurance” Series includes “WealthAhead II Savings Insurance – Prime” and “WealthAhead II Savings Insurance – Supreme”.

[5] The interim owner arrangement is applicable only to policies issued in Hong Kong.

[6] Up to nine currency options are available: Renminbi (RMB), US dollar (USD), British pound sterling (GBP), Euro (EUR), Canadian dollar (CAD), Australian dollar (AUD), Singapore dollar (SGD), Hong Kong dollar (HKD) and Macanese pataca (MOP) (MOP is applicable only to policies issued in Macau). Different policy returns are offered for each currency.

[7] Starting from the 3rd policy anniversary, the currency conversion option may be exercised within 30 days after each policy anniversary. There is no limit on the number of times this option may be exercised; however, only one application may be made per policy year. For details, please refer to the relevant product brochure and policy contract.

[8] Starting from the 5th policy anniversary, the policy value lock-in option may be exercised once within 30 days after each policy anniversary to lock in the guaranteed cash value, the cash value of the non-guaranteed reversionary bonus, and the cash value of the terminal bonus.

[9] The information refers to the offering of dual currency accounts under a policy. The information refers to Hong Kong market only and is based on a comparison among participating savings plans with reversionary bonus offered by insurers for Long-Term Businesses as defined by the Insurance Authority in the Register of Authorised Insurers in Hong Kong as of July 2025.

[10] The designation of the contingent owner or interim owner and the application for taking up the policy ownership are subject to the approval of the Company at its absolute discretion and must fulfill certain conditions. The interim owner is only applicable to policies issued in Hong Kong. For details, please refer to the relevant product brochure and policy contract.

[11] The designation of contingent insured and the application for replacement of the insured are subject to the approval of AXA at its absolute discretion and must fulfill certain conditions. For details, please refer to the relevant product brochure and policy contract.

[12] From the 1st policy anniversary onwards, the Change of Insured Option can be exercised an unlimited number of times. Written application for the exercise of the Change of Insured Option should be made by you and such application is subject to the administrative rules, underwriting requirements and approval of the Company.

[13] In the unfortunate event of the policy owner’s mental incapacitation or physical incapacitation which certified by a registered medical practitioner, the designated executor can act on your behalf to make a one-time withdrawal from the policy, and the appointment of designated executor and the application of withdrawal are subject to the approval of AXA at its absolute discretion and must fulfill certain conditions. For details, please refer to the relevant product brochure and policy contract.

[14] You may specify the death benefit settlement start age of each beneficiary, provided that such age shall not exceed the age of the relevant beneficiary at the date of designation by more than 30 years. 

[15] The above total offer includes i) a premium rebate and ii) a guaranteed preferential interest rate for prepaid premiums. Offer ii) is only applicable to 5-year policies with US dollar policy currency and requires a lump sum payment of five times the first annual premium of the basic plan upon application. Terms and conditions apply.

 

About AXA Hong Kong and Macau

AXA Hong Kong and Macau is a member of the AXA Group, a leading global insurer with presence in 50 markets and serving 95 million customers worldwide. Our purpose is to act for human progress by protecting what matters.

As one of the most diversified insurers in Hong Kong, we offer integrated solutions across Life, Health and General Insurance. We are the largest General Insurance provider and a major Health and Employee Benefits provider. Our aim is to not only be the insurer to provide comprehensive protection to our customers, but also a holistic partner to the individuals, businesses and community we serve. At the core of our service commitment is continuous product & service innovation and customer experience enrichment, which is achieved through actively listening to our customers’ needs and leveraging and investing in technology and digital transformation.

We embrace our responsibility to be a driving force against climate change and a force for good to create shared value for our community. We are proud to be the first to address the importance of mental health through different products and services and thought leading iconic research. Our overall Sustainability Strategy, with emphasis on climate strategy and biodiversity commitment, is developed based on TCFD recommendations. We are committed to integrating environmental, social and governance factors across our business and strive to contribute to a sustainable future through 3 distinct roles – as an investor, insurer and an exemplary company.

THIS PRESS RELEASE IS AVAILABLE ON AXA’S WEBSITE: AXA.COM.HK 

IMPORTANT LEGAL INFORMATION AND CAUTIONARY STATEMENTS CONCERNING FORWARD-LOOKING STATEMENTS
Certain statements contained herein may be forward-looking statements including, but not limited to, statements that are predictions of or indicate future events, trends, plans or objectives. Undue reliance should not be placed on such statements because, by their nature, they are subject to known and unknown risks and uncertainties and can be affected by other factors that could cause AXA’s actual results to differ materially from those expressed or implied in the forward-looking statements. Please refer to Part 4 – “Risk factors and risk management” of AXA’s Universal Registration Document for the year ended December 31, 2020, for a description of certain important factors, risks and uncertainties that may affect AXA’s business, and/or results of operations. AXA undertakes no obligation to publicly update or revise any of these forward-looking statements, whether to reflect new information, future events or circumstances or otherwise, except as part of applicable regulatory or legal obligations.

Day 2 of 2025 Sustainable Global Leaders Conference: Nobel Laureate Shares AI Insights, Major ESG Achievements Announced

By
Advertorial Desk
-

SHANGHAI, Oct. 20, 2025 /PRNewswire/ — Approved by China’s State Council, 2025 Sustainable Global Leaders Conference is being held in Huangpu District, Shanghai, from October 16 to 18. Under the theme “Joining Hands to Address Challenges: Global Action, Innovation, and Sustainable Growth”, the conference brings together global expertise to explore new pathways for sustainable development and inject powerful “Chinese momentum” into global sustainability governance.

The conference is co-hosted by the World Green Design Organization (WGDO) and Sina Group, with the IFRS Foundation Beijing Office as a co-organizer. It is jointly organized by Sina Finance and the WGDO Beijing Representative Office, and supported by the People’s Government of Huangpu District, Shanghai.

On October 17, the second day, Distinguished international political figures attended the event, including Kolinda Grabar-Kitarović, the 4th President of the Republic of Croatia, Member of International Olympic Committee (IOC), Vuk Jeremić, President of the Center for International Relations and Sustainable Development, Former Foreign Minister of Serbia, Former President of the United Nations General Assembly, and H.E. Salvador Moncada, Ambassador of Honduras to China.

Liu Jun, President of Industrial and Commercial Bank of China and Wang Zhiheng, president of Agricultural Bank of China. Liu also held a dialogue with Michael Levitt, Nobel Laureate in Chemistry, on AI Innovation Powers Sustainable Development.

Other notable attendees included Tu Guangshao, Co-chair of the ESG Leaders Association Forum, YAN Shidong, Director General, Center for Environmental Education and Communications of Ministry of Ecology and Environment, P.R.C, He Qing, Secretary of the CPC Shanghai Municipal State-owned Assets Supervision and Administration Committee, Xu Huili, Deputy Secretary of the CPC Huangpu District Committee, District Mayor of Huangpu, and Deng Qingxu, CEO of Sina Finance.

A series of significant ESG-related reports were released during the conference, including: 2024 China Alcohol Drinks ESG Development Index Report, ESG Disclosure Progress Report — Based on AI Tools, The 2025 Disclosure Dividend — A Comprehensive Assessment of Business Resilience in a Rapidly Changing Environment, Sustainable Development: Breaking Through Growth Barriers — Carbon Neutrality and Executive Insights 2025, and Green Development Research Findings by Beijing National Institute of ESG.

The conference also welcomed leading figures from international organizations, academia, finance, business, and sports. Michael Levitt, Michael Levitt, 2013 Nobel Prize Laureate in Chemistry, Member of the National Academy of Sciences, Fellow of the Royal Society, and Professor of Structural Biology at Stanford University in the United States delivered a keynote address on How AI Is Reshaping the Future of Industry and Society. Jared Diamond, Professor of Geography, University of California, Los Angeles; Author of Guns, Germs, and Steel presented a special lecture titled The Next Chapter of Human History: Integrating Health, Environment, and Governance.

Other distinguished speakers included Liang Tao, Liang Tao, former Vice Chairman of the China Banking and Insurance Regulatory Commission, Zhao Yan, Zhao Yan, Founder of Bloomage Biotech, Bloomage International, Dinan Huang, Chairman of Shenergy (Group) Co., Ltd., Liu Liya, Vice President of Shanghai University of Finance and Economics, Zhao Ruirui, former Chinese women’s volleyball player and Olympic champion, and Qin Shuo, Humanities and Finance Observer, Organizer of Chin@ Moments.

As a key international platform for sustainability dialogue, 2025 Sustainable Global Leaders Conference fosters global conversations and industrial collaboration with an open, cooperative, and mutually beneficial approach. It brings together governments, enterprises, academia, institutions, and social organizations to explore practical pathways and long-term mechanisms for sustainable development.

Looking ahead, the conference will continue to promote the exchange and transformation of green innovations, deepen integration with local economy, technological innovation, and financial capital, and help Shanghai evolve into a globally influential model city for sustainable development — delivering China’s green commitments and actions to the world.

 

Yamaha to Launch Subscription Version of “Mobile VOCALOID™ Editor”

By
Advertorial Desk
-

Create Vocaloid songs anytime, anywhere.

HAMAMATSU, Japan, Oct. 20, 2025 /PRNewswire/ — Yamaha Corporation will launch a subscription version of the “Mobile VOCALOID Editor an app for iPhone and iPad that allows users to create VOCALOID songs, on October 20 (Mon.) via the App Store. With this new subscription service, users can now enjoy an even easier way to experience VOCALOID music creation.

Yamaha Software “Mobile VOCALOID Editor” (Subscription Version)
Yamaha Software “Mobile VOCALOID Editor” (Subscription Version)

Yamaha Software “Mobile VOCALOID Editor” (Subscription Version) URL: https://www.vocaloid.com/en/mveditor/

Developed by Yamaha in 2003, VOCALOID singing voice synthesis technology and software creates vocals for songs using lyrics and a melody (musical notation) as input. Released in 2015, “Mobile VOCALOID Editor” is an app for iPhone/iPad that allows users to create songs by simply tapping notes and lyrics on the screen, and has been widely used by many users for its intuitive workflow and wide range of available voicebanks.

With the introduction of the subscription model, the app now features the VOCALOID:AI synthesis engine, the same engine used in the PC/Mac versions of VOCALOID6 which uses artificial intelligence to synthesize more natural, richly expressive singing voices. The new voicebank “asa,” which features a delicate and translucent singing voice, is included as a standard feature, and in addition to the existing voicebanks of characters such as Hatsune Miku, IA, and v flower, the voicebank options have been expanded to include VOCALOID:AI compatible voicebanks such as AI Megpoid and Otomachi Una.

To encourage users to start creating VOCALOID songs more freely and easily with “Mobile VOCALOID Editor,” we have prepared short phrases, such as those that can be freely used for arrangement songs, on the official website.

[Retail Prices and Release Dates]

Product name

Retail price (USD)

Release date

Mobile VOCALOID Editor

$3.99/month

October 20

Additional voicebank VY1

$9.99

October 20

Additional voicebank
(excluding VY1)

$19.99

October 20

*Please refer to the official shop for the price of each product: https://www.vocaloid.com/en/mveditor/

[Features of Mobile VOCALOID Editor]

  • Authentic VOCALOID Singing, Anytime, Anywhere

“Mobile VOCALOID Editor” allows users to enjoy authentic vocal production anytime and anywhere by entering lyrics in English for each note of the melody in the piano roll on their smartphone or tablet screen. External MIDI devices compatible with iOS can also be connected for input, allowing for more flexible music production in combination with external devices and apps.

  • Equipped with the new voicebank “asa“

The subscription version of “Mobile VOCALOID Editor” includes the new voicebank “asa.” This voicebank features a “delicate and translucent singing voice” and allows users to enjoy the natural and expressive singing voice unique to VOCALOID:AI.

  • Enables in-app purchases of additional voicebanks

When you want to increase the variety of singing voices or create songs with voicebanks that you like, you can download and purchase over 40 additional character voicebanks such as Hatsune Miku, Megpoid, Otomachi Una, and IA from the in-app store screen. Additional voicebanks are planned to be released sequentially, and by switching to a voicebank of your choice, you can further expand the range of your music production.

  • Launch Campaign

To celebrate the launch of the subscription version of “Mobile VOCALOID Editor,” we are holding a “Voicebank of Your Choice Giveaway Campaign” for users who post their created songs on social media between today and November 9 (Sun.). Please check the official “Mobile VOCALOID Editor” website for campaign details.

[Product Summary]

Supported OS

iOS 17 or higher

Supported Devices

iPhone/iPad

Fee

$3.99/month

Included Voicebanks (Free)

2 voicebanks (asa / VY1_Lite)

Paid Voicebanks

Over 40 types / ＄19,99 (USD) (more to be added)

Number of Tracks

32 tracks

Loadable VOCALOID Sequence Files

VSQX, VPR (VOCALOID6)

* VOCALOID and VOCALO are trademarks or registered trademarks of Yamaha Corporation.

* Other product names, company names, etc. in this document are trademarks or registered trademarks of this company and other companies.

About Yamaha Corporation

Founded in 1887, the Yamaha Group has established itself as a global leader in manufacturing musical instruments and audio products while continuing to engage in various business activities to grow services related to sound and music. Yamaha operates over 60 subsidiaries worldwide, dedicated to serving millions of customers across six continents, focusing on delivering excellence in quality and innovation, prioritizing our sustainability efforts and contributing to people’s “well-being.” To learn more, visit https://www.yamaha.com/en/.

ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma

By
Advertorial Desk
-

BERLIN, Oct. 20, 2025 /PRNewswire/ — At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by RemeGen Co., Ltd. was presented at the Presidential Symposium by Professor Jun Guo from Beijing Cancer Hospital. It’s the first time a research led by Chinese scholars in the field of urological oncology has ever been selected in this honorable session. The full manuscript was simultaneously published online in The New England Journal of Medicine (NEJM). This marks the first time that the results of a Chinese evidence-based medical research in the field of urothelial carcinoma have been recognized by both an authoritative international academic conference and a top-tier journal.

The results showed that the RC48-C016 study met the dual primary endpoints of Progression-Free Survival (PFS) and Overall Survival (OS). The Blinded Independent Central Review (BICR)-assessed median PFS reached 13.1 months, and the median OS reached 31.5 months, demonstrating both statistical and clinical significance.

The RC48-C016 trial is by now the only randomized controlled study from China providing high-level evidence for HER2-ADC as a first-line treatment of HER2-expressing (IHC 1+/2+/3+) locally advanced/metastatic urothelial carcinoma (la/mUC). The results garnered high attention and sparked lively discussion among global scholars upon release.

Comprehensive Superiority: Meeting Both PFS and OS Primary Endpoints

On the afternoon of October 19 (local time), a pivotal moment arrived at the ESMO Congress: Professor Guo Jun, the principal investigator of the RC48-C016 study, delivered a featured oral presentation at the Presidential Symposium, unveiling the breakthrough results globally for the first time.

The RC48-C016 study is a randomized controlled, multi-center, phase III clinical trial. It compares the efficacy and safety of disitamab vedotin combined with toripalimab versus gemcitabine combined with cisplatin or carboplatin in patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who have not received systemic treatment and have HER2 expression (HER2 IHC 1+/2+/3+). The study was initiated in June 2022, with 76 clinical research centers across the country participating, and a total of 484 patients were enrolled. The dual primary endpoints of the study are PFS and OS, and the secondary endpoints include objective response rate (ORR), disease control rate (DCR), and safety, etc.

Results as of March 31, 2025, showed:

  • Regarding PFS, the median PFS in the disitamab vedotin combination group reached 13.1 months, more than doubling the 6.5 months in the chemotherapy group and reducing the risk of disease progression or death by 64% (Hazard Ratio [HR] =0.36, 95% CI: 0.28 – 0.46, P < 0.0001).
  • The OS data were equally exciting. In this interim survival analysis, the median OS in the disitamab vedotin combination group was 31.5 months, compared to 16.9 months in the platinum-based chemotherapy group. The delayed disease progression has been well translated into long-term survival benefit as the overall survival time almost doubled as compared to chemotherapy, with a 46% reduction in the risk of death (HR = 0.54, 95% CI: 0.41 – 0.73, P < 0.0001).
  • Regarding tumor response, the ORR assessed by BICR reached 76.1% in the disitamab vedotin combination group, far exceeding the 50.2% in the chemotherapy group. For disease control, the DCR in the disitamab vedotin combination group reached 91.4%, significantly higher than the 77.6% in the chemotherapy group.
  • In key subgroup analyses, significant improvements in median PFS and median OS were observed in the disitamab vedotin combination group compared to the platinum-based chemotherapy across subgroups, regardless of cisplatin eligibility, HER2 expression status, or primary tumor site.
  • Furthermore, the combination regimen demonstrated a better safety profile. The overall incidence of Grade ≥3 treatment-related adverse events was only 55.1% in the disitamab vedotin combination group, significantly lower than the 86.9% in the chemotherapy group.

“This is the world’s first large-scale Phase III randomized controlled clinical study in the first-line treatment of HER2-expressing Chinese mUC patients, which demonstrated that HER2-ADC combined with immunotherapy was superior to standard platinum-based chemotherapy, potentially establishing the combination therapy of disitamab vedotin and immunotherapy as the standard of care in the first-line treatment of advanced HER2-expressing mUC. This not only signifies that China’s innovative drug development is leading transformations in cancer treatment globally but also provides critical rationale for exploring similar combination strategies in treating other cancers.” As Professor Guo Jun commented, the result of the RC48-C016 study confirmed that the efficacy of disitamab vedotin + toripalimab combination regimen surpassed that of traditional chemotherapy as first-line treatment for advanced mUC, potentially marking a major shift in the treatment landscape for urothelial carcinoma. It promotes innovation in Chinese diagnostic and treatment pathways while providing valuable evidence for global clinical practice.

During the subsequent expert commentary session, Professor Andrea Necchi from Italy’s IRCCS San Raffaele Hospital spoke highly of RC48-C016 study. He pointed out that the study represents a significant breakthrough in the treatment of HER2-positive urothelial carcinoma. Compared to chemotherapy, the combination therapy of disitamab vedotin and toripalimab significantly improves patients’ PFS and OS, demonstrating substantial statistical significance and clinical value, thereby offering a novel treatment option for this patient population.

Precision Treatment, Benefiting the Full Spectrum of HER2-Expressing Population (IHC 1+/2+/3+)

Urothelial carcinoma is the most common malignant tumor of the urinary system, representing a significant area of clinical unmet need.

Chinese researchers have been at the forefront of exploring HER2-ADC therapy for UC. The HER2-ADC disitamab vedotin was first approved in China in 2021 for the treatment of HER2-overexpressing (IHC 2+/3+) advanced or metastatic urothelial carcinoma, demonstrating excellent efficacy and consistent safety with that observed in prior clinical trials.

RC48-C016 study prospectively extended its clinical design to the full HER2-expressing population (IHC 1+/2+/3+). Among 765 patients tested for HER2, 632 patients had HER2-expressing characteristics (IHC 1+/2+/3+), accounting for approximately 82.6% of the tested population. The study enrolled 484 patients, who were randomized in a 1:1 ratio to groups. Stratification factors were pre-specified in the study design, primarily including cisplatin eligibility, HER2 expression status (IHC 1+ vs. IHC 2+/3+), and presence of visceral metastasis.

The results showed that the efficacy observed in the disitamab vedotin plus toripalimab regimen were consistent across all pre-specified subgroups. Regardless of HER2 expression status, cisplatin eligibility, or whether the tumor originated in the upper or lower urinary tract, disitamab vedotin combined with toripalimab significantly improved PFS and OS compared to chemotherapy, robustly demonstrating its benefit for the full demonstrating its benefit for the full HER2-expressing population (IHC 1+/2+/3+) with urothelial carcinoma.

“The significant survival benefit achieved by disitamab vedotin combined with toripalimab is not subject to the level of HER2 expression or cisplatin eligibility status, delivering benefit to populations with different characteristics,” Professor Guo Jun stated, noting that its benefit for the full HER2-expressing population (IHC 1+/2+/3+) is one of the most groundbreaking findings of this study.

Disitamab Vedotin Combined with Immunotherapy, Establishing a New Benchmark in UC First-Line Treatment

Undoubtedly, RC48-C016 study is a milestone in the global first-line treatment landscape for advanced urothelial carcinoma, signifying a fundamental shift in the treatment paradigm for HER2-expressing patients:

Firstly, RC48-C016 study is the world’s first Phase III head-to-head trial to demonstrate that the combination of HER2-ADC and immunotherapy is significantly superior to traditional platinum-based chemotherapy in the first-line treatment of HER2-expressing (IHC 1+/2+/3+) advanced urothelial carcinoma. The release of its outstanding data on PFS, OS, ORR, and safety provides strong decision-making basis for clinicians, which will promote this combination to become a new first-line treatment standard for Chinese mUC patients and is expected to rewrite clinical guidelines.

Secondly, the study successfully implements the concept of precision medicine in urothelial carcinoma based on significant biomarker characteristics. By extending the beneficiary population from the traditional HER2-high (IHC 2+/3+) to the full HER2-expressing (IHC 1+/2+/3+) population, it enables over 80% of urothelial carcinoma patients to potentially benefit significantly from this treatment regimen. In the current clinical practice in China where HER2 routine detection in urothelial carcinoma has been achieved, the study provides a preferred precise treatment plan for the majority of patients and precise basis for anti-HER2 treatment, promoting a comprehensive upgrade in the global treatment concept and strategy for urothelial carcinoma and leading the continuous exploration of this combination therapy in different disease stages of urothelial carcinoma.

Thirdly, this combination regimen substantially reduces the toxicity associated with traditional platinum-based chemotherapy, significantly improving patient treatment tolerance and compliance, and providing a foundation for subsequent continuous therapy, achieving an optimized balance between tumor control, long-term survival, and quality of life.

Since its marketing four years ago, disitamab vedotin, relying on its outstanding efficacy, has achieved a progress from late-line to first-line treatment in the field of urothelial carcinoma, comprehensively breaking through the bottlenecks of traditional chemotherapy and continuously expanding the boundaries of its clinical value. The revelation of RC48-C016 study data once again demonstrates its huge clinical treatment potential.

Based on the breakthrough results of the RC48-C016 study, RemeGen Co., Ltd. submitted a New Drug Application (NDA) in China in July of this year for the new indication of disitamab vedotin combined with toripalimab for the first-line treatment of HER2-expressing locally advanced or metastatic urothelial carcinoma. This will not only address domestic clinical needs but also holds the potential to become a “Chinese Solution” influencing the global treatment landscape.

It is believed that with extended follow-up, disitamab vedotin will continue to yield clinical benefit data for broader treatment prospects.

1...1,9241,9251,926...6,309Page 1,925 of 6,309